KEAP1 and diabetic kidney disease: The Keap1-Nrf2 system is thought to be a crucial role in kidney oxidative injury and considered as a prospective target for kidney disease [43, 44], so proteasome inhibitor MG132 could inhibit Nrf2 proteasomal degradation and promote antioxidative activity, having the protective efficacy on diabetes nephropathy [45].